Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of regorafenib plus pembrolizumab in advanced or metastatic hepatocellular carcinoma after prior PD-1/PD-L1 inhibitor therapy
MOH_2021-01-13_009659Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Efficacy. Started Jan 2021; status: completed.
02
Drugs
regorafenibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2021-01-13_009659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-13_009659.